Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

He and his team then compared the diagnoses for hair loss in these patients’ medical records and found that those prescribed ...

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to ...

Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ...

Both semaglutide and tirzepatide would need big price cuts to be seen as a good buy for the US healthcare system.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Senators questioned Novo Nordisk CEO Lars Jørgensen on Tuesday at a hearing over the costs of Ozempic, Wegovy and similar weight loss drugs, which are cheaper in other countries. The CEO of ...

Eli Lilly (LLY) has launched its weight-loss and diabetes drug, Mounjaro (tirzepatide), in India, securing a first-mover ...

Lilly beats Novo Nordisk to launch weight-loss drug in India Mounjaro's 5 mg ... subject to doctor's prescription. Mounjaro carries a list price of $1,086.37 for each monthly fill in the U.S ...